TP53, MDM2, NQO1, and Susceptibility to Cervical Cancer
Authors:
- 1 March 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (3) , 755-761
Abstract
Host genetic variability modifies the risk of cervical cancer in women infected with oncogenic human papillomavirus (HPV). Studies have reported an association of the TP53 codon 72 arginine and cervical cancer, but the results are inconsistent. We examined the association of this single nucleotide polymorphism (SNP) in women with cervical cancer and cervical intraepithelial neoplasia grade 3, using a family-based association test. We further explored SNPs in two genes that regulate p53 stability: MDM2 (SNP309) and NQO1 (SNP609, SNP465). We also examined the relationship between host genotype and tumor HPV type. We genotyped 577 patients and their biological parents and/or siblings, using PCR-RFLP or Taqman assays. HPVs were typed by sequence-based methods. The transmission/disequilibrium test was used to detect disease-susceptibility alleles. The arginine peptide of TP53 codon 72 was overtransmitted in Caucasian families (P = 0.043), and the significance of this finding was enhanced in a subgroup of women infected with HPV16- and/or HPV18-related HPVs (P = 0.026). Allele C of NQO1 SNP609 was also overtransmitted in all cases (P = 0.026). We found no association between MDM2 SNP309 or NQO1 SNP465 and cervical cancer. Our results indicate that functional polymorphisms in TP53 codon 72 and NQO1 SNP609 associate with the risk of cervical cancer especially in women infected with type 16– and/or type 18–related HPVs. Cancer Epidemiol Biomarkers Prev; 19(3); 755–61Keywords
This publication has 33 references indexed in Scilit:
- TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studiesThe Lancet Oncology, 2009
- CD83 polymorphisms and cervical cancer riskGynecologic Oncology, 2009
- CD83 Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical CancerCancer Research, 2007
- No relationship observed between human p53 codon‐72 genotype and HPV‐associated cervical cancer in a population group with a low arginine‐72 allele frequencyInternational Journal of Immunogenetics, 2007
- NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser Polymorphism and the Risk of Lung, Bladder, and Colorectal Cancers: a Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2006
- Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neckOral Oncology, 2005
- Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinomaGynecologic Oncology, 2005
- Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjectsGynecologic Oncology, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Denaturing High-Performance Liquid Chromatography for Detecting and Typing Genital Human PapillomavirusJournal of Clinical Microbiology, 2003